Skip to main content
Top

2020 | OriginalPaper | Hoofdstuk

34. Oncologie bij kinderen

Auteurs : Dr. J. H. M. Merks, Dr. S. L. A. Plasschaert, Dr. C. van den Bos

Gepubliceerd in: Leerboek oncologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

De afgelopen decennia is de kans op genezing voor een kind met kanker fors gestegen, dankzij toepassing van intensieve chemo- en radiotherapie en chirurgie in goed opgezette klinische studies. Ondanks deze forse verbetering zijn er nog steeds groepen patiënten met een slechte prognose. De behandeling van kinderen met kanker in Nederland is sinds juni 2018 gecentraliseerd in het Prinses Máxima Centrum voor Kinderoncologie in Utrecht, in nauwe samenwerking met een netwerk van geselecteerde ‘shared care’ centra in academische en algemene ziekenhuizen. In het Prinses Máxima Centrum zijn zorg en research gecentraliseerd en samengebracht met als doel uiteindelijk elk kind met kanker te genezen met zo min mogelijk late gevolgen. Omdat de vaak intensieve behandeling gegeven wordt aan kinderen in groei en ontwikkeling met een vaak goede en lange levensverwachting, is de kans op het ontstaan van late gevolgen na de behandeling groot. Het voorkómen van deze late gevolgen door de juiste therapiekeuzes, alsmede een toegesneden en langdurige follow-up, is daarmee een essentieel onderdeel van de kinderoncologische zorg.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
go back to reference Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, et al.; European paediatric Soft tissue sarcoma Study Group. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(11):1566–75. Epub 24 September 2019. Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, et al.; European paediatric Soft tissue sarcoma Study Group. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(11):1566–75. Epub 24 September 2019.
go back to reference Chisholm JC, Merks JHM, Casanova M, Bisogno G, Orbach D, Gentet JC, et al.; European paediatric Soft tissue sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017;83:177–84. Chisholm JC, Merks JHM, Casanova M, Bisogno G, Orbach D, Gentet JC, et al.; European paediatric Soft tissue sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017;83:177–84.
go back to reference Den Boer ML, Van Slechtenhorst M, De Menezes RX, Cheok MH, Bijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34.CrossRef Den Boer ML, Van Slechtenhorst M, De Menezes RX, Cheok MH, Bijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34.CrossRef
go back to reference Holleman A, Cheok MH, Den Boer ML. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533–42.CrossRef Holleman A, Cheok MH, Den Boer ML. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533–42.CrossRef
go back to reference Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Eng J Med. 2018;378:439–48.CrossRef Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Eng J Med. 2018;378:439–48.CrossRef
go back to reference Moorman AV, Enshael A, Schwab C, Wade R, Chilton L, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymophoblastic leukemia. Blood. 2014;124(9):1434–44.CrossRef Moorman AV, Enshael A, Schwab C, Wade R, Chilton L, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymophoblastic leukemia. Blood. 2014;124(9):1434–44.CrossRef
go back to reference Oberlin O, Rey A, De Sanchez TJ, Martelli H, Jenney ME, Scopinaro M, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the international society of pediatric oncology MMT95 study. J Clin Oncol. 2012;30(20):2457–65.CrossRef Oberlin O, Rey A, De Sanchez TJ, Martelli H, Jenney ME, Scopinaro M, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the international society of pediatric oncology MMT95 study. J Clin Oncol. 2012;30(20):2457–65.CrossRef
go back to reference Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26(14):2384–9.CrossRefPubMedCentral Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26(14):2384–9.CrossRefPubMedCentral
go back to reference Pieters R, Schrappe M, De Lorenzo P. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–50.CrossRef Pieters R, Schrappe M, De Lorenzo P. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–50.CrossRef
go back to reference Pieters R, De Groot-Kruseman H, Van der Velden V, Fiocco M, Van den Berh H, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL 10 from the Dutch childhood oncology group. J Clin Oncol. 2016;34(22):2591–601.CrossRef Pieters R, De Groot-Kruseman H, Van der Velden V, Fiocco M, Van den Berh H, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL 10 from the Dutch childhood oncology group. J Clin Oncol. 2016;34(22):2591–601.CrossRef
go back to reference Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2016. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2016.
go back to reference Pui Ch, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.CrossRefPubMedCentral Pui Ch, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.CrossRefPubMedCentral
go back to reference Van Dongen JJ, Seriu T, Panzer-Grümayer ER. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–8.CrossRef Van Dongen JJ, Seriu T, Panzer-Grümayer ER. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–8.CrossRef
go back to reference Van der Sluis IM, Uyttebroeck A, Pieters R. Acute lymfatische leukemie. In: Kaspers G, Dors N, Luijpers W, Benoit T, redactie. Leerboek kinderoncologie. Utrecht: De Tijdstroom; 2019. Van der Sluis IM, Uyttebroeck A, Pieters R. Acute lymfatische leukemie. In: Kaspers G, Dors N, Luijpers W, Benoit T, redactie. Leerboek kinderoncologie. Utrecht: De Tijdstroom; 2019.
go back to reference Kaspers G, Dors N. Luijpers W, Benoit T, redactie. Leerboek kinderoncologie. Utrecht: De Tijdstroom; 2019. Kaspers G, Dors N. Luijpers W, Benoit T, redactie. Leerboek kinderoncologie. Utrecht: De Tijdstroom; 2019.
go back to reference Kazak AE, Rourke MT, Alderfer MA, Pai A, Reilly AF, Meadows AT. Evidence-based assessment, intervention and psychosocial care in pediatric oncology: a blueprint for comprehensive services across treatment. J Pediatr Psychol. 2007;32(9):1099–110. Kazak AE, Rourke MT, Alderfer MA, Pai A, Reilly AF, Meadows AT. Evidence-based assessment, intervention and psychosocial care in pediatric oncology: a blueprint for comprehensive services across treatment. J Pediatr Psychol. 2007;32(9):1099–110.
go back to reference Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerged from molecular classification of CNS-PNETs. Cell. 2016;164:1060–72. Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerged from molecular classification of CNS-PNETs. Cell. 2016;164:1060–72.
go back to reference Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropath. 2012;123:465–72. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropath. 2012;123:465–72.
Metagegevens
Titel
Oncologie bij kinderen
Auteurs
Dr. J. H. M. Merks
Dr. S. L. A. Plasschaert
Dr. C. van den Bos
Copyright
2020
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2449-1_34